Replagal is a prescription medication used in the treatment of Fabry disease, a rare genetic disorder characterized by the buildup of a specific type of fat in the body's cells. This accumulation can lead to a wide range of symptoms, including pain, kidney failure, heart disease, and stroke. Replagal, known generically as agalsidase alfa, works by replacing the deficient enzyme in patients with Fabry disease, helping to break down the accumulated fat and alleviate symptoms. It is administered through intravenous infusion, typically every two weeks, and is considered a form of enzyme replacement therapy (ERT). As with any medication, the use of Replagal should be closely monitored by healthcare professionals to manage any potential side effects and to ensure its effectiveness in the treatment regimen.